Osteoporosis

• 10 million people (8 million women and 2 million men) age 50+ already have osteoporosis and another 34 million (30 million women and 14 million men) have low bone mass. That is 55% of the people in the US in that age category, according to the National Osteoporosis Foundation.
• The number of people with osteoporosis is expected to grow by 20% and those with low bone mass will grow by 18% over the next eight years.
• Osteoporosis is not part of the normal aging process, although many believe this to be true. Younger generations, due to lifestyle and diet, are putting themselves at a larger risk than the generation that went before them.
• Knowledge (Ntx bone loss analysis) and intervention (changes in lifestyle, diet, and NHRT when needed) are crucial to stem the growth rate of osteoporosis and low bone mass in the future.

Bone Markers such as the NTx bone loss analysis are essential

• Lack of efficacy may reach levels as high as 20% for HRT and 15% for oral bisphosphonates, as evidenced by a failure to gain vertebral bone mineral density (BMD).
• The Restore^® BioBalance (NTx) bone loss test can be done 3 months following initiation of therapy, helping individuals and their physicians make an early determination as to the drug's skeletal effect.
• Compare this to the 1 to 2 years required for BMD testing and you'll understand why bone marker technology plays such an essential role in patient management. BMD testing simply is not enough.
• It's up to you. Wait 1 to 2 years for a BMD, or get actionable results in just 3 months with Restore^® BioBalance (NTx) bone loss test.

Cost

• Healthcare costs have been and continue to rise at rates that are becoming unaffordable for employers who sponsor health insurance plans, as well as for individuals who do not have access to employer sponsored plans.
• BMD testing ranges from $200 to $350 per scan.
• Restore^® BioBalance (NTx) bone loss test is an affordable and economic alternative to BMD testing.
• Helps assess individuals who will receive the greatest long-term skeletal benefit from hormonal antiresorptive therapy.
  • High NTx baseline results indicate which individuals will show the greatest increase in bone mineral density (BMD) with HRT therapy.
• Determine the probability for a decrease in bone mass in postmenopausal individuals if they do not initiate HRT. Bone mass is determined by DEXA.
  • High NTx baseline results identify individuals who are at the greatest risk for bone loss at the spine after one year if not treated with HRT.
  • Individuals not receiving HRT who have high baseline Urine NTx results (>67 nM BCE/mM Creatinine Urine NTx) are at 17 times greater risk for bone loss at the spine after one year.
• Monitor response to antiresorptive therapy in postmenopausal individuals as well as those diagnosed with or at risk for osteoporosis.
  • In as soon as 3 months, NTx can determine the effect of an antiresorptive therapy on bone resorption.
• Provides vital information to help health care professionals counsel individuals on the effect of antiresorptive therapy on bone resorption and encourage patient compliance and continuation of therapy.